GSK GSK plc Forecast, Technical & Fundamental Analysis

GSK in +2.10% Uptrend, rising for three consecutive days on September 17, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GSK advanced for three days, in 204 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for GSK's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

GSK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 35 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

The Moving Average Convergence Divergence Histogram (MACD) for GSK turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 20 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 43%.

GSK moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GSK crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 58%.

The 50-day moving average for GSK moved below the 200-day moving average on September 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

The Aroon Indicator for GSK entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.266) is normal, around the industry mean (19.199). P/E Ratio (15.948) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.037) settles around the average of (0.025) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.